Dupuytren Contracture Recurrence Following Treatment With Collagenase Clostridium Histolyticum (CORDLESS [Collagenase Option for Reduction of Dupuytren Long-Term Evaluation of Safety Study]): 5-Year Data

Peimer, Clayton A.; Blazar, Philip E.; Coleman, Stephen; Kaplan, F. Thomas D.; Smith, Ted; Lindau, Tommy

doi:10.1016/j.jhsa.2015.04.036

Cited by 194 publications

(168 citation statements)

References 18 publications

Supporting

Mentioning

144

Contrasting

Unclassified

Order By: Relevance

“…This increases to 66% and 40% respectively by 5 years after treatment. 11 We have studied a sample of patients who had been treated with CCH to determine their satisfaction with the treatment, to identify reasons for dissatisfaction, to determine whether satisfaction changes over time, and to consider whether satisfaction could be improved.…”

mentioning

confidence: 99%

Patient Satisfaction With Collagenase

Bradley

Warwick

2016

The Journal of Hand Surgery

View full text Add to dashboard Cite

mentioning

confidence: 99%

Patient Satisfaction With Collagenase

Bradley

Warwick

2016

The Journal of Hand Surgery

View full text Add to dashboard Cite

“…A longer follow-up period is warranted to assess contracture recurrence, which has been reported in 47% of patients within 5 years after a conventional CCH dose. 15 For patients with Dupuytren contractures involving the MCP and PIP joints in the same digit, distributing the maximum volume that can be withdrawn from a single reconstituted CCH vial can provide efficacy at both joints similar to previously published series with a comparable complication rate. Utilizing the residual CCH that is typically discarded may provide a cost savings to patients and insurance payers.…”

Section: Resultsmentioning

confidence: 57%

The Use of Residual Collagenase for Single Digits With Multiple-Joint Dupuytren Contractures

Grandizio

Akoon

Heimbach

et al. 2017

The Journal of Hand Surgery

View full text Add to dashboard Cite

“…Peimer et al 13 have published a series of 950 patients. Compared with our reported 1-year relapse rate of 15%, for MP joints, this study found a 39% 5-year relapse rate for MP joints, suggesting that a good initial result does not guarantee that relapse will not occur.…”

Section: Discussionmentioning

confidence: 99%

Difference in Success Treating Proximal Interphalangeal and Metacarpophalangeal Joints with Collagenase: Results of 208 Treatments

Hansen

Werlinrud

Larsen

et al. 2017

Plastic and Reconstructive Surgery - Global Open

View full text Add to dashboard Cite

Background:Dupuytren disease (DD) is a fibroproliferative disorder of the palmar fasciae causing extension deficit and impaired hand function. Treatment with injection of collagenase clostridium histolyticum (CCH) is a nonsurgical treatment method. The aim of this study was to evaluate the difference in efficiency and recurrence at 12-month follow-up when treating metacarpophalangeal (MP) and proximal interphalangeal (PIP) joints with CCH. None of the patients had received previous treatments of their condition.Methods:This study is a prospective study of a consecutive series of patients with DD presenting with an extension deficit greater than 20° affecting the MP or PIP joint.Results:We found a mean reduction in extension deficit of 47° (91%) for MP joints and 47° (76%) for PIP joints. Full correction (max 5° deficit) was achieved in 76% of MP and 28% of PIP joints. Skin rupture was seen in 34% of treatments. The 1-year relapse rate was 15% for MP and 67% for PIP joints. The reduction in quickDASH score was only statistically significant for MP joints at 1 year. Eighty-one percent of all patients reported being satisfied or very satisfied. No major adverse events were recorded.Conclusion:Excellent results can be achieved in the treatment of MP-joint contractures, whereas the success rate is significantly lower and recurrence rate is greater for PIP joints.

show abstract

Dupuytren Contracture Recurrence Following Treatment With Collagenase Clostridium Histolyticum (CORDLESS [Collagenase Option for Reduction of Dupuytren Long-Term Evaluation of Safety Study]): 5-Year Data

Cited by 194 publications

References 18 publications

Patient Satisfaction With Collagenase

Patient Satisfaction With Collagenase

The Use of Residual Collagenase for Single Digits With Multiple-Joint Dupuytren Contractures

Difference in Success Treating Proximal Interphalangeal and Metacarpophalangeal Joints with Collagenase: Results of 208 Treatments

Contact Info

Product

Resources

About